A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Top Cited Papers
Open Access
- 17 February 2017
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (2), 441
- https://doi.org/10.3390/ijms18020441
Abstract
Gaucher disease (GD, ORPHA355) is a rare, autosomal recessive genetic disorder. It is caused by a deficiency of the lysosomal enzyme, glucocerebrosidase, which leads to an accumulation of its substrate, glucosylceramide, in macrophages. In the general population, its incidence is approximately 1/40,000 to 1/60,000 births, rising to 1/800 in Ashkenazi Jews. The main cause of the cytopenia, splenomegaly, hepatomegaly, and bone lesions associated with the disease is considered to be the infiltration of the bone marrow, spleen, and liver by Gaucher cells. Type-1 Gaucher disease, which affects the majority of patients (90% in Europe and USA, but less in other regions), is characterized by effects on the viscera, whereas types 2 and 3 are also associated with neurological impairment, either severe in type 2 or variable in type 3. A diagnosis of GD can be confirmed by demonstrating the deficiency of acid glucocerebrosidase activity in leukocytes. Mutations in the GBA1 gene should be identified as they may be of prognostic value in some cases. Patients with type-1 GD—but also carriers of GBA1 mutation—have been found to be predisposed to developing Parkinson’s disease, and the risk of neoplasia associated with the disease is still subject to discussion. Disease-specific treatment consists of intravenous enzyme replacement therapy (ERT) using one of the currently available molecules (imiglucerase, velaglucerase, or taliglucerase). Orally administered inhibitors of glucosylceramide biosynthesis can also be used (miglustat or eliglustat).This publication has 203 references indexed in Scilit:
- A mutation in SCARB2 is a modifier in gaucher diseaseHuman Mutation, 2011
- Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodiesJournal of Inherited Metabolic Disease, 2011
- Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage‐targeted enzyme replacement therapyJournal of Inherited Metabolic Disease, 2010
- Hyperferritinemia and iron overload in type 1 Gaucher diseaseAmerican Journal of Hematology, 2010
- High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher diseaseJournal of Inherited Metabolic Disease, 2010
- The risk of Parkinson's disease in type 1 Gaucher diseaseJournal of Inherited Metabolic Disease, 2010
- Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinicsEMBO Molecular Medicine, 2009
- The Erlenmeyer flask bone deformity in the skeletal dysplasiasAmerican Journal of Medical Genetics Part A, 2009
- The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patientsAmerican Journal of Hematology, 2009
- Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literatureAnnals of Hematology, 2008